Aytu Biopharma (AYTU) Gains from Investment Securities (2018 - 2022)
Aytu Biopharma (AYTU) posted quarterly Gains from Investment Securities of $75000.0 for Q4 2022, down 72.92% year-over-year from $277000.0 in Q4 2021, and down 86.36% quarter-over-quarter from $550000.0 in Q2 2022.
Aytu Biopharma (AYTU) Gains from Investment Securities (2018 - 2022) Analysis & Trends
Aytu Biopharma (AYTU) has reported Gains from Investment Securities for 5 consecutive years, with $75000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Gains from Investment Securities fell 72.92% year-over-year to $75000.0; the TTM figure through Dec 2023 stood at -$632000.0 (down 78.03% YoY), while the FY2023 annual figure was -$1.0 million, down 373.93% from the prior year.
- Gains from Investment Securities retreated to $75000.0 in Q4 2022 per AYTU's latest filing, from $550000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $3.3 million in Q4 2020 and bottomed at -$10.5 million in Q2 2020.
- Historically, Gains from Investment Securities has averaged -$828613.9 across 5 years, with a median of $29500.0 in 2019.
- Annual changes were most pronounced in 2020 — Gains from Investment Securities soared 21986.67% — and 2021, when it sank 91.64%.
- Aytu Biopharma's Gains from Investment Securities stood at $4633.0 in 2018, then jumped by 223.76% to $15000.0 in 2019, then jumped by 21986.67% to $3.3 million in 2020, then tumbled by 91.64% to $277000.0 in 2021, then slumped by 72.92% to $75000.0 in 2022.
- Business Quant data shows AYTU's Gains from Investment Securities at $75000.0 in Q4 2022, $550000.0 in Q2 2022, and -$1.3 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Aytu Biopharma | 24.70 Mn | -2.01 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 75,000.00 |
| Dec 31, 2022 | 75,000.00 |
| Jun 30, 2022 | 550,000.00 |
| Jun 30, 2022 | 550,000.00 |
| Mar 31, 2022 | -1.26 Mn |
| Mar 31, 2022 | -1.26 Mn |
| Dec 31, 2021 | 277,000.00 |
| Dec 31, 2021 | 277,000.00 |
| Sep 30, 2021 | 219,000.00 |
| Sep 30, 2021 | 219,000.00 |
| Jun 30, 2021 | -2.68 Mn |
| Jun 30, 2021 | -2.68 Mn |
| Dec 31, 2020 | 3.31 Mn |
| Dec 31, 2020 | 3.31 Mn |
| Sep 30, 2020 | -2,000.00 |
| Sep 30, 2020 | -2,000.00 |
| Jun 30, 2020 | -10.50 Mn |
| Jun 30, 2020 | -10.50 Mn |
| Mar 31, 2020 | 44,000.00 |
| Mar 31, 2020 | 44,000.00 |